在皮肤冠状动脉干预和相关结果期间使用康格罗尔的救助
Abhishek Chaturvedi1, Andrew P Hill1, Patrick Creechan2
1Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.
The American journal of cardiology
|July 22, 2025
概括
康格洛尔是一种静脉注射的P2Y12抑制剂,在皮肤冠状动脉干预 (PCI) 期间的血栓性并发症中显示出作为救助疗法的希望. 这项研究表明,它可以安全地改善血液流动,并解决血栓,为其他治疗提供了替代方案.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 穿皮冠状动脉干预 (PCI) 可能因血栓事件而复杂化.
- 有限的数据存在于康格罗尔作为这些并发症的救助疗法的有效性.
- 康格洛尔是一种静脉注射的P2Y12受体抑制剂,用于PCI.
研究的目的:
- 为了评估康格罗尔在PCI期间作为救助疗法使用时的安全性和有效性.
- 评估接受康格罗尔治疗血栓并发症的患者的血管学和临床结果.
- 为了确定康格罗尔是否可以作为糖蛋白IIb/IIIa抑制剂的替代品.
主要方法:
- 在PCI期间从2016年1月到2023年12月接受康格罗尔作为救助治疗的患者的回顾性查.
- 血管检查结果的分析,包括心肌梗塞中血栓溶解 (TIMI) 流量和血栓分辨率.
- 评估住院临床结果:缺血事件,严重出血和住院时间.
主要成果:
- 在2680名PCI患者中,Cangrelor被用于67名 (2.5%) 的救助疗法.
- 救助的原因包括缓慢的流量 (40.3%),没有回流 (23.9%),支架血栓形成 (22.4%),以及侧枝阻塞 (16.4%).
- 在TIMI流量 (1.3至2.7) 中显著改善,在86.7%的支架血栓症病例中完全溶解了血栓,其中11.9%的缺血事件和4.5%的大型出血.
结论:
- 康格洛尔是一种安全且可行的临时救助策略,用于PCI期间的血栓性并发症.
- 它有效地改善了血管图流,并解决了血栓,特别是在支架血栓形成的情况下.
- 在特定的PCI场景中,康格洛尔为糖蛋白IIb/IIIa抑制剂提供了可行的替代品.
相关概念视频
01:28Acute Coronary Syndrome IV: Interprofessional Care
30
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
30
01:30Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
01:27Coronary Artery Disease V: Interprofessional Care
34
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
34
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
693
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
693
01:27Peripheral Artery Disease III: Interprofessional Care
30
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
30
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
648
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
648